



Published in final edited form as:

*Chembiochem*. 2019 July 01; 20(13): 1712–1716. doi:10.1002/cbic.201800811.

## A Phosphinate-Containing Fluorophore Capable of Selectively Inducing Apoptosis in Cancer Cells

Xinqi Zhou<sup>a</sup>, Yuan Fang<sup>a</sup>, Lauren Lesiak<sup>a</sup>, Cliff I. Stains<sup>a,b,c</sup>

<sup>[a]</sup>Department of Chemistry, University of Nebraska Lincoln, NE 68588 (USA)

<sup>[b]</sup>Nebraska Center for Integrated Biomolecular Communication University of Nebraska, Lincoln, NE 68588 (USA)

<sup>[c]</sup>Cancer Genes and Molecular Regulation Program Fred & Pamela Buffet Cancer Center, University of Nebraska Medical Center Omaha, NE 68198 (USA)

### Abstract

Chemotherapeutic agents generally suffer from off-target cytotoxicity in noncancerous cell types, leading to undesired side effects. As a result, significant effort has been put into identifying compounds that are selective for cancerous over noncancerous cell types. Our laboratory has recently developed a series of near-infrared (NIR) fluorophores containing a phosphinate functionality at the bridging position of a xanthene scaffold, termed Nebraska Red (NR) fluorophores. Herein, we report the selective cytotoxicity of one NR derivative, NR744, against HeLa (cervical cancer) cells versus NIH–3T3 (noncancerous fibroblast) cells. Mechanistic studies based on the NIR fluorescence signal of NR744 showed distinct subcellular localization in HeLa (mitochondrial) versus NIH–3T3 (lysosomal) that resulted from the elevated mitochondrial potential in HeLa cells. This study provides a new, NIR scaffold for the further development of reagents for targeted cancer therapy.

### Graphical Abstract



**On target:** A near-infrared fluorophore can selectively induce cell death in cancer cells. The induction of apoptotic markers as well as the inhibition of migration is demonstrated. This scaffold could be used for the further development of reagents for targeted cancer therapy.

cstains2@unl.edu.

Conflict of Interest

The authors declare no conflict of interest.

Supporting information and the ORCID identification numbers for the authors of this article can be found under <https://doi.org/10.1002/cbic.201800811>.

## Keywords

apoptosis; cancer; cytotoxicity; fluorescence probes; phosphinate

---

## Introduction

Cancer is the second leading cause of death in the USA, with nearly one in every four deaths being caused by this disease.<sup>[1]</sup> Indeed, the US Food and Drug Administration (FDA) has approved more than 200 anticancer drugs over the past few decades. However, one factor that continues to complicate treatment is the off-target toxicity observed for commonly used chemotherapeutic drugs.<sup>[2]</sup> Recently, drug-discovery campaigns have turned towards the development of targeted molecules with tissue-specific activities.<sup>[3]</sup> Such compounds could potentially be used at higher dosages with less off-target effects. At the same time, significant attention has been focused on the development of NIR fluorophores for applications in in vivo imaging and image-guided surgery.<sup>[4]</sup> These NIR probes circumvent issues associated with the light scattering and endogenous background fluorescence of biological species. For example, two FDA-approved NIR contrast agents, indocyanine green (ICG) and methylene blue (MB), have been extensively employed to visualize tumors.<sup>[5]</sup> However, neither of these dyes shows significant toxicity to the labeled cells. Furthermore, although some chemotherapeutic drugs exhibit weak or moderate fluorescence under illumination in the visible region of the spectrum,<sup>[6]</sup> none displays NIR absorption and emission. Thus, we sought to combine the benefits of selective toxicity and NIR imaging into one molecular scaffold.

One factor that can be used to discriminate between cancerous tissue and surrounding normal tissue is altered metabolic function, known as the Warburg effect.<sup>[7]</sup> Corresponding increases in mitochondrial membrane potential (MMP,  $\Delta\psi$ ) and the production of reactive oxygen species in cancer cells have been well documented.<sup>[8]</sup> For example, the mitochondria of cancer cells display an increased MMP of  $\approx 60$  mV compared to normal epithelial cells.<sup>[9]</sup> These factors led to the discovery that delocalized lipophilic cations (DLCs) are selectively taken up into the mitochondria of cancer cells and, in certain cases, elicit a cytotoxic response.<sup>[10]</sup> Interestingly, the fluorophore known as rhodamine-123 (Rh-123, Scheme 1) is the first reported DLC with selective toxicity to carcinoma cells.<sup>[10a,b]</sup> Since this observation, several elegant strategies, based on altered MMP, for the delivery of compounds to cancer cells have been described.<sup>[11]</sup> However, there remains a need to identify smallmolecule fluorophores with NIR fluorescence excitation and emission that display selective toxicity to cancer cells. Such molecules would provide a starting-point for the generation of simplified reagents for both the visualization and potential treatment of tumors.

Our laboratory has recently reported a series of NIR fluorophores based on the incorporation of a phosphinate functionality at the bridging position of rhodamine-based fluorophores (Scheme 1).<sup>[12]</sup> These fluorophores display bright NIR fluorescence and provide a scaffold for the development of chemical biology tools such as self-reporting delivery reagents<sup>[12]</sup> or turn-on fluorescent probes.<sup>[13]</sup> Herein, we report our observation of the selective

mitochondrial localization and toxicity of NR<sub>744</sub> in cancer cells. As with previously described DLCs,<sup>[14]</sup> NR<sub>744</sub> localization is dependent upon MMP. However, NR<sub>744</sub> provides a robust NIR signal that can be used to visualize dye uptake ( $\lambda_{\text{ex}} = 744 \text{ nm}$ ,  $\lambda_{\text{em}} = 764 \text{ nm}$ ,  $\epsilon = 8 \times 10^4$ , and  $\Phi = 0.16$ ). In addition, the chemical reactivity of phosphorous allows for the potential, long-term development of improved reagents for selectively imaging and subsequently treating cancer cells.

## Results and Discussion

Before constructing imaging agents from NR fluorophores, we sought to fully define the cellular localization and toxicity of our initial NR derivatives by using HeLa cells as a model cell line. During these experiments, we observed that three of the NR derivatives were nontoxic up to 50  $\mu\text{M}$ , whereas NR<sub>744</sub> displayed clear toxicity at low-micromolar concentrations (Figure S1 in the Supporting Information). The phosphinate-containing compounds (NR<sub>666</sub> and NR<sub>698</sub>) did not cross the cell membrane,<sup>[12]</sup> whereas the phosphinate ethyl ester-containing derivatives NR<sub>700</sub> and NR<sub>744</sub> localized to lysosomes (Figure S2) or the mitochondria (Figure 1 A, Pearson's coefficient  $R = 0.92$ ), respectively. Comparing NR<sub>698</sub> and NR<sub>744</sub>, we hypothesized that the phosphinate ethyl ester of NR<sub>744</sub> facilitates cell uptake. In addition, we have previously shown that the ester group of NR<sub>744</sub> is stable to hydrolysis in buffer at pH 7.4,<sup>[12]</sup> maintaining a net positive charge in the molecule that might contribute to mitochondrial localization. Moreover, more than 80 % of NR<sub>744</sub> survived 48 h of incubation in culture medium containing 50 % fetal bovine serum (FBS) at 37 °C (Figure S3). The localization of NR<sub>700</sub> to lysosomes indicates that the lipophilicity of NR<sub>744</sub> might also play a role in mitochondrial localization.<sup>[15]</sup> However, it should be noted that the phosphinate ethyl ester of NR<sub>700</sub> undergoes spontaneous hydrolysis in aqueous solutions to yield NR<sub>666</sub> (with a half-life of 27 min at pH 7.4),<sup>[12]</sup> potentially altering the net charge of the molecule in cells. To further investigate the mechanism of NR<sub>744</sub> localization, HeLa cells were treated with carbonyl cyanide *m*-chlorophenyl hydrazone (CCCP, a known proton uncoupler) or oligomycin A (an ATP synthase inhibitor). Importantly, CCCP is known to decrease MMP whereas oligomycin A increases it.<sup>[16]</sup> Thus, if NR<sub>744</sub> localization is dependent upon MMP, decreased mitochondrial localization in CCCP-treated cells and increased mitochondrial accumulation in oligomycin A-treated cells would be anticipated. Gratifyingly, a clear decrease in mitochondrial localization was observed in the presence of CCCP, and oligomycin A treatment led to a sharp increase in mitochondrial accumulation of NR<sub>744</sub> (Figure 1 B). These data indicate that localization of NR<sub>744</sub> in cells with a normal MMP might differ from that observed in HeLa cells. Accordingly, we incubated NR<sub>744</sub> with NIH-3T3 cells and observed localization to lysosomes (Figure 1 C, Pearson's coefficient  $R = 0.93$ ). Together, these data indicate that NR<sub>744</sub> toxicity in HeLa is due to localization to the mitochondria and that the localization pattern of NR<sub>744</sub> changes based on the MMP.

We next asked whether the toxicity of NR<sub>744</sub> would be altered in cells with different MMPs. At relatively high concentrations (> 25  $\mu\text{M}$ , Figure S4), toxicity in NIH-3T3 cells was observed. However, using lower concentrations of NR<sub>744</sub> (5  $\mu\text{M}$ ) enabled discrimination between NIH-3T3 (90.3  $\pm$  3.2 % viability) and HeLa cells (57.9  $\pm$  2.2 % viability) after incubation with NR<sub>744</sub> for 24 h (Figures S1 and S4). We observed an enhancement in selectivity upon increasing the incubation time of NR<sub>744</sub> to 48 h, yielding IC<sub>50</sub> values of 453

nm and 12.6  $\mu\text{M}$ , respectively for HeLa and NIH-3T3 cells (Figure 2). Under these conditions, selective cell death in HeLa cells could be induced while NIH-3T3 cells remained viable. Additionally, NR<sub>744</sub> was found to be toxic across a panel of cancerous cell lines including MCF-7 (breast), HepG2 (liver), and HCT-116 (colon; Figure S5).

Encouraged by these results, we evaluated NR<sub>744</sub> toxicity in a co-culture system containing both HeLa and NIH-3T3 cells. In order to distinguish each cell type, we first labeled pure populations of cells with fluorescent dyes that are retained for  $\approx$  3– 6 generations. This differential labeling with violet (HeLa) or red (NIH-3T3) markers allowed cell viability to be analyzed by using flow cytometry to probe the well-established apoptotic marker, phosphatidylserine<sup>[17]</sup> in each cell type within the co-cultures. Cells were labeled with cell-tracking dyes and subsequently co-cultured in the presence or absence of NR<sub>744</sub>. Each cell type was gated by using its respective cell-tracker dye fluorescence channel, and viability was probed by using an annexin V–Alexa 488 conjugate, to determine the extent of phosphatidylserine present on the cell surface.<sup>[18]</sup> Importantly, no appreciable difference in phosphatidylserine labeling was observed in cells treated with DMSO (Figures 3 and S6); however, distinct 77 and 270 % increases in phosphatidylserine exposure were observed for HeLa cells when incubated with NR<sub>744</sub> (Figures 3 and S6). This difference in the induction of apoptosis could also be replicated in cells that were independently cultured and treated with NR<sub>744</sub> (Figure S7). Thus, NR<sub>744</sub> is capable of selectively inducing apoptosis in cancerous cells in the presence of noncancerous cells.

Lastly, we sought to determine the effect of NR<sub>744</sub> on cell migration in a wound-healing assay.<sup>[19]</sup> Cell migration is a critical processes involved in the normal physiology of immune responses and tissue homeostasis as well as disease-associated processes such as metastasis.<sup>[20]</sup> Confluent monolayers of cells were wounded and subsequently cultured in the presence of 5  $\mu\text{M}$  NR<sub>744</sub> for 24 h. Over this time period, NIH-3T3 cells displayed complete healing of the wound, with essentially no difference between treated and control cultures (Figure 4 A). However, a significant inhibition of wound closure was observed for HeLa cells cultured in the presence of NR<sub>744</sub> (17 % closure) versus solvent (36 % closure, Figure 4 B). Taken together, these data demonstrate that NR<sub>744</sub> can selectivity inhibit both the growth and motility of cancerous cells.

## Conclusion

In summary, we have reported the selective toxicity of a phosphinate-containing NIR fluorophore in cells with increased mitochondrial membrane potential. Selectivity was confirmed by multiple readouts including ATP production, quantification of apoptotic markers, and wound healing. In addition, the molecular mechanism of NR<sub>744</sub> toxicity was investigated; this indicated that NR<sub>744</sub> toxicity is due to increased MMP in HeLa cells, similar to previously reported delocalized lipophilic cations. In the long term, NR<sub>744</sub> can be used as a starting-point to develop improved tools for imaging and potential therapeutic applications. For example, further modification by adding heavy atoms could potentially afford a NIR photosensitizer.<sup>[21]</sup> In addition, the unique reactivity of phosphorous,<sup>[12]</sup> coupled with the extensive literature surrounding xanthene-based turn-on fluorescent probes,<sup>[22]</sup> could provide a means to further increase the selectivity of NR<sub>744</sub> for certain cell types.

## Experimental Section

### Fluorophore synthesis and characterization:

The synthesis and characterization of fluorophores used in this study have been reported previously.<sup>[12]</sup>

**NR<sub>744</sub> hydrolytic stability:** A solution of NR<sub>744</sub> (5  $\mu\text{M}$ ) in 0.5 % DMSO was prepared in phosphate-buffered saline (PBS), Dulbecco's modified Eagle's medium (DMEM) with 10 % FBS, or DMEM with 50 % FBS. Solutions were aliquoted (2 mL) into the center three wells of a 24-well clear-bottom plate. In the wells surrounding the samples, sterilized water (2 mL) was added to prevent evaporation. The plate was then placed in a mammalian cell-culture incubator at 37°C under a 5 % CO<sub>2</sub>, humidified atmosphere. Samples (100  $\mu\text{L}$ ) were removed at 0, 14, 24, 38, and 48 h and mixed with acetonitrile (100  $\mu\text{L}$ ) containing 0.1 % TFA. Samples were centrifuged at 21130  $g$  for 2 min. HPLC separation was conducted with a Waters 1525 Binary HPLC pump and a 2489 UV/Vis detector by using a gradient of 30–95 % acetonitrile containing 0.1 % trifluoroacetic acid (TFA) over 45 min in water containing 0.1 % TFA. Samples (80  $\mu\text{L}$ ) were injected into the HPLC and monitored at 700 nm. The area of the peak corresponding to NR<sub>744</sub> was determined for each sample and normalized to the 0 h time point.

**Cell culture:** NIH-3T3 (ATCC, CRL-1658), HeLa (ATCC, CCL-2), MCF-7 (ATCC, HTB-22), and HepG2 (ATCC, HB-8065) cells were grown in DMEM (Life Technologies, 10566016) supplemented with 10 % FBS (Life Technologies, 10082147) and 1 x Anti-Anti (Life Technologies, 15240062). HCT-116 cells (ATCC, CCL-247) were cultured in McCoy's 5A (Gibco, 16600082) containing 10 % FBS and 1 x Anti-Anti. Cells were maintained at 37°C under a 5 % CO<sub>2</sub>, humidified atmosphere.

**Confocal microscopy and data analysis:** Cells were grown to  $\approx$  80 % confluency on glass-bottomed, 12-well plates (MatTek, P12G-1.5–14-F). After the culture medium had been aspirated, the cells were washed three times with prewarmed Dulbecco's phosphate-buffered saline (DPBS; Life Tech, 14040117) and incubated with the indicated concentration of NR<sub>744</sub>, along with the indicated subcellular organelle tracker, for 30 min in culture medium. Cells were then washed with DPBS three times and imaged in DPBS. Confocal microscopy was performed with a Nikon A1R-TiE live-cell imaging confocal system. Laser lines used include blue (405 nm), green (488 nm), and far-red (640 nm). ImageJ software was used for data analysis.

**Cell toxicity assays:** Cells were seeded in a 96-well plate ( $2 \times 10^4$  cells in each well) and were incubated with the indicated concentration of NR<sub>744</sub> in culture medium containing 0.5 % DMSO. After the indicated time period, cell viability was assessed by using the CellTiter-Glo 2.0 Assay (Promega) according to the manufacturer's protocol.

**Wound-healing assays:** The assay was performed according to a previously reported protocol.<sup>[19]</sup> Briefly, cells were cultured on a 60 mm petri dish to 80 % confluency. A P200 pipet tip was used to create the wound, and the cells were washed and incubated with culture medium containing the indicated concentration of NR<sub>744</sub>. Images of wounded cells were

immediately taken. After 24 h of incubation, the same spot was imaged. ImageJ software was used for data analysis.

**Flow cytometry assays:** Cells ( $6 \times 10^6$ ) were washed with DPBS before resuspension in DPBS (1 mL) containing cell tracker violet (20  $\mu$ M; for HeLa cells) or cell tracker red (20  $\mu$ M; for NIH-3T3 cells). After 30 min of incubation, excess dye was removed by centrifugation (100 *g*, 5 min), and cells were seeded into individual wells or co-cultured in 12-well plates at  $\approx$  30–40 % confluency. After 24 h, the culture medium was removed, and cells were washed three times with DPBS. Cells were then incubated in culture medium containing NR<sub>744</sub> for the indicated time periods. Apoptotic cell percentages under different conditions were analyzed by annexin V–Alexa Fluor 488 (Life Technologies, V13241) labeling according to the manufacturer’s protocol. When analyzing annexin V staining, different cell populations were gated by using cell tracker fluorescence (violet and red).

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.




## Acknowledgements

We thank the Morrison Microscopy Core Facility for assistance with the confocal fluorescence microscopy. We also thank the Flow Cytometry Service Center for assistance with the flow cytometry-related experiments. This work was funded by the NIH (R35GM119751) and the University of Nebraska–Lincoln. The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

## References


- [1]. Health, United States, 2016: With Chartbook on Long-Term Trends in Health, National Center for Health Statistics, Hyattsville, MD, 2017.
- [2]. Zheng YQ, Ji XY, Yu BC, Ji KL, Gallo D, Csizmadia E, Zhu MY, Choudhury MR, De La Cruz LKC, Chittavong V, Pan ZX, Yuan ZN, Otterbein LE, Wang BH, *Nat. Chem* 2018, 10, 787–794. [PubMed: 29760413]
- [3]. a) Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, Overington JP, *Nat. Rev. Drug Discovery* 2017, 16, 19–34; [PubMed: 27910877] b) Mamoshina P, Volosnikova M, Ozerov IV, Putin E, Skibina E, Cortese F, Zhavoronkov A, *Front. Genet* 2018, 9, 242; [PubMed: 30050560] c) Schneider G, Schmidt-Supprian M, Rad R, Saur D, *Nat. Rev. Cancer* 2017, 17, 239–253; [PubMed: 28256574] d) Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H, *BMC Syst. Biol* 2017, 11, 87. [PubMed: 28984210]
- [4]. a) Ding F, Zhan Y, Lu X, Sun Y, *Chem. Sci* 2018, 9, 4370–4380; [PubMed: 29896378] b) Podgorski K, Terpetschnig E, Klochko OP, Obukhova OM, Haas K, *PLoS One* 2012, 7, e51980; [PubMed: 23251670] c) Cosco ED, Caram JR, Bruns OT, Franke D, Day RA, Farr EP, Bawendi MG, Sletten EM, *Angew. Chem. Int. Ed* 2017, 56, 13126–13129; *Angew. Chem.* 2017, 129, 13306 – 13309; d) Gorka AP, Nani RR, Schnermann MJ, *Acc. Chem. Res* 2018, 51, 3226–3235. [PubMed: 30418020]
- [5]. a) Alander JT, Kaartinen I, Laakso A, Patila T, Spillmann T, Tuchin VV, Venermo M, Valisuo P, *Int. J. Biomed. Imaging* 2012, 2012, 940585; [PubMed: 22577366] b) Kim W, Applegate BE, *Opt. Lett* 2015, 40, 1426–1429. [PubMed: 25831349]
- [6]. Aaron JJ, Trajkovska S, *Curr. Drug Targets* 2006, 7, 1067–1081. [PubMed: 17017886]
- [7]. Vander Heiden MG, Cantley LC, Thompson CB, *Science* 2009, 324, 1029–1033. [PubMed: 19460998]
- [8]. Smith RA, Hartley RC, Cocheme HM, Murphy MP, *Trends Pharmacol. Sci* 2012, 33, 341–352; [PubMed: 22521106] Murphy MP, *Biochem. J* 2009, 417, 1–13. [PubMed: 19061483]

- [9]. Murphy MP, *Biochim. Biophys. Acta Bioenerg* 2008, 1777, 1028–1031.
- [10]. a) Bernal SD, Lampidis TJ, Summerhayes IC, Chen LB, *Science* 1982, 218, 1117–1119; [PubMed: 7146897] b) Bernal SD, Lampidis TJ, McIsaac RM, Chen LB, *Science* 1983, 222, 169–172; [PubMed: 6623064] c) Smith RA, Hartley RC, Murphy MP, *Antioxid. Redox Signaling* 2011, 15, 3021–3038.
- [11]. a) Milane L, Trivedi M, Singh A, Talekar M, Amiji M, *J. Controlled Release* 2015, 207, 40–58; b) Chen ZP, Li M, Zhang LJ, He JY, Wu L, Xiao YY, Duan JA, Cai T, Li WD, *J. Drug Targeting* 2016, 24, 492–502; c) Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, VasquezVivar J, Cheng G, Lopez M, Kalyanaraman B, *Chem. Rev* 2017, 117, 10043–10120. [PubMed: 28654243]
- [12]. Zhou X, Lai R, Beck JR, Li H, Stains CI, *Chem. Commun* 2016, 52, 12290–12293.
- [13]. Chai XY, Xiao J, Li M, Wang CM, An HY, Li C, Li YT, Zhang DZ, Cui XY, Wang T, *Chem. Eur. J* 2018, 24, 14506–14512. [PubMed: 30019781]
- [14]. a) Sun XC, Wong JR, Song KL, Hu JL, Garlid KD, Chen LB, *Cancer Res* 1994, 54, 1465–1471; [PubMed: 8137249] b) Fantin VR, Berardi MJ, Scorrano L, Korsmeyer SJ, Leder P, *Cancer Cell* 2002, 2, 29–42; [PubMed: 12150823] c) Koya K, Li Y, Wang H, Ukai T, Tatsuta N, Kawakami M, Shishido, Chen LB, *Cancer Res* 1996, 56, 538–543. [PubMed: 8564968]
- [15]. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC, *J. Pharmacol. Exp. Ther* 2008, 324, 95–102. [PubMed: 17947497]
- [16]. a) Jastroch M, Divakaruni AS, Mookerjee S, Treberg JR, Brand MD, *Essays Biochem* 2010, 47, 53–67; [PubMed: 20533900] b) Felle H, Bentrup FW, *Biochim. Biophys. Acta Biomembr* 1977, 464, 179–187.
- [17]. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM, *J. Immunol* 1992, 148, 2207–2216. [PubMed: 1545126]
- [18]. Tait JF, Gibson D, *Arch. Biochem. Biophys* 1992, 298, 187–191. [PubMed: 1388011]
- [19]. Liang CC, Park AY, Guan JL, *Nat. Protoc* 2007, 2, 329–333. [PubMed: 17406593]
- [20]. Vicente-Manzanares M, Webb DJ, Horwitz AR, *J. Cell Sci* 2005, 118, 4917–4919. [PubMed: 16254237]
- [21]. Gorman A, Killoran J, O’Shea C, Kenna T, Gallagher WM, O’Shea DF, *J. Am. Chem. Soc* 2004, 126, 10619–10631. [PubMed: 15327320]
- [22]. Chen X, Pradhan T, Wang F, Kim J, Yoon J, *Chem. Rev* 2012, 112, 1910–1956. [PubMed: 22040233]

**Rh-123****NR<sub>700</sub>** R = OCH<sub>2</sub>CH<sub>3</sub>**NR<sub>666</sub>** R = O<sup>-</sup>**NR<sub>744</sub>** R = OCH<sub>2</sub>CH<sub>3</sub>**NR<sub>698</sub>** R = O<sup>-</sup>


**Scheme 1.**  
Structures of Rh-123 and NR derivatives.






**Figure 1.**


NR<sub>744</sub> localization. A) Co-localization of NR<sub>744</sub> and MitoTracker Green (MTG) in HeLa cells. B) NR<sub>744</sub> localization in HeLa cells is dependent upon the mitochondrial membrane potential. NR<sub>744</sub> (5 μM) and CCCP (1 μM), DMSO, or oligomycin A (2 μg mL<sup>-1</sup>) were incubated with cells for 30 min. Cells were washed and immediately imaged under identical conditions. C) Co-localization of NR<sub>744</sub> with LysoTracker Green (LTG) in NIH-3T3 cells. All scale bars: 10 μm.



**Figure 2.** Selective toxicity of NR<sub>744</sub>. Cells were incubated with NR<sub>744</sub> at various concentrations for 48 h. Increased toxicity in A) HeLa versus B) NIH-3T3 cells is observed. Error bars represent the standard deviation of triplicate experiments.



**Figure 3.** Annexin V labeling in co-cultures of HeLa (■) and NIH-3T3 (■) cells visualized by flow cytometry. HeLa and NIH-3T3 cells were co-cultured in the presence or absence of 5 μM NR<sub>744</sub> for the indicated times, and annexin V labeling was evaluated by gating the appropriate cell tracker color for each cell population. Error bars represent the standard deviation of triplicate experiments.



**Figure 4.** Wound healing in HeLa and NIH-3T3 cells treated with NR<sub>744</sub>. Representative figures of wound closure for A) NIH-3T3 cells and B) HeLa cells after incubation with blank (DMSO) or NR<sub>744</sub> (5  $\mu$ M) for the indicated times. C) Quantification of the percentage of open wound area in HeLa cells. Error bars represent the standard deviation of triplicate experiments; \*  $p < 0.05$ .